Immunomodulatory effects of IL-33 and IL-25 in an ovalbumin-induced allergic rhinitis mouse model

C Yang, N Chen, XL Tang, XH Qian, CP Cai

Article ID: 3953
Vol 35, Issue 2, 2021
DOI: https://doi.org/10.23812/20-615-A
Received: 9 May 2021; Accepted: 9 May 2021; Available online: 9 May 2021; Issue release: 9 May 2021

Abstract

Both interleukin (IL)-33 and IL-25 induce Th2-type cytokine production by various cell types, suggesting that they may contribute to development of allergic disorders, however, the immunomodulatory effects of IL-33 and IL-25 in ovalbumin (OVA)-induced allergic rhinitis (AR) remain unclear. In the present study, anti-IL-33 and anti-IL-25 Abs were administrated intranasally during rechallenge in OVA-induced AR. Immunomodulatory effects were evaluated by measuring nasal rubbing, sneezing occurrence, serum OVA-specific antibodies, Th2 immune responses, neutrophil, eosinophil and mast cell recruitment into the nasal mucosa. We found that treatment with anti-IL-33 Ab markedly reduced nasal rubbing, sneezing events, Th2 immune responses, serum OVA-specific IgE and IgG1 levels, mucosal neutrophil, eosinophil and mast cell infiltration. In contrast, the effect of IL-25 antagonism was limited to attenuating the Th2 immune responses, and neutrophil and eosinophil infiltration. These observations indicate that IL-33 and IL-25 play a pathogenic role in an established AR mouse model, with a greater contribution of IL-33 than IL-25. Our findings suggest that IL-33 neutralization may be a potential approach for treatment of AR.


Keywords

IL-25;IL-33;allergic rhinitis;ovalbumin


References

Supporting Agencies



Copyright (c) 2021 C Yang, N Chen, XL Tang, XH Qian, CP Cai




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).